Bio-Path Holdings, Inc. (NASDAQ:BPTH – Get Free Report) was the recipient of a large growth in short interest during the month of October. As of October 15th, there was short interest totalling 388,600 shares, a growth of 3,947.9% from the September 30th total of 9,600 shares. Approximately 10.5% of the company’s shares are sold short. Based on an average daily volume of 1,390,000 shares, the days-to-cover ratio is currently 0.3 days.
Bio-Path Stock Performance
Shares of Bio-Path stock opened at $1.10 on Friday. The business has a 50-day moving average of $1.05 and a 200 day moving average of $1.82. Bio-Path has a 12 month low of $0.85 and a 12 month high of $14.42.
Bio-Path (NASDAQ:BPTH – Get Free Report) last announced its earnings results on Thursday, August 15th. The company reported ($1.16) EPS for the quarter, beating analysts’ consensus estimates of ($1.54) by $0.38. During the same period in the previous year, the firm earned ($10.60) EPS. Research analysts predict that Bio-Path will post -6.2 EPS for the current year.
Hedge Funds Weigh In On Bio-Path
Wall Street Analysts Forecast Growth
BPTH has been the subject of a number of recent analyst reports. StockNews.com began coverage on Bio-Path in a research report on Wednesday. They set a “sell” rating for the company. Roth Mkm restated a “buy” rating and set a $20.00 target price on shares of Bio-Path in a report on Monday, July 8th.
Check Out Our Latest Research Report on Bio-Path
About Bio-Path
Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
Read More
- Five stocks we like better than Bio-Path
- What is a Death Cross in Stocks?
- Texas Roadhouse Stock Steering for New Highs This Year
- Insider Buying Explained: What Investors Need to Know
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- Canada Bond Market Holiday: How to Invest and Trade
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.